Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.54−0.08 (-13.14%)
Close on Nov 17, 2026Market cap $211.76MP/E 2.5Yield –
Standard BioTools operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Standard BioTools's operating income for the twelve months ending Jun 30, 2026 was -$95.47M. For fiscal 2025 it was -$110.25M. The highest annual figure on record is -$14.57M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$110.25M | – |
| FY2024 | Dec 31, 2024 | -$127.49M | – |
| FY2023 | Dec 31, 2023 | -$76.60M | – |
| FY2022 | Dec 31, 2022 | -$116.21M | – |
| FY2021 | Dec 31, 2021 | -$67.46M | – |
| FY2020 | Dec 31, 2020 | -$51.04M | – |
| FY2019 | Dec 31, 2019 | -$51.84M | – |
| FY2018 | Dec 31, 2018 | -$48.16M | – |
| FY2017 | Dec 31, 2017 | -$58.36M | – |
| FY2016 | Dec 31, 2016 | -$73.19M | – |
| FY2015 | Dec 31, 2015 | -$50.16M | – |
| FY2014 | Dec 31, 2014 | -$51.84M | – |
| FY2013 | Dec 31, 2013 | -$18.65M | – |
| FY2012 | Dec 31, 2012 | -$18.07M | – |
| FY2011 | Dec 31, 2011 | -$18.57M | – |
| FY2010 | Dec 31, 2010 | -$14.57M | – |
| FY2009 | Dec 31, 2009 | -$18.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$25.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$26.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$60.18M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.50M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.61M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.32M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.73M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.94M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.18M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.82M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.21M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.12M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.63M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.79M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.74M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$16.49M | – |
| Q1 FY2017 | Mar 31, 2017 | -$17.54M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.70M | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.48M | – |
See a number that looks wrong?